Get the Stockscreener App
369.53
0.53%
1.93
After Hours:
368.51
-1.02
-0.28%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $369.53, with a volume of 2.41M.
It is up +0.53% in the last 24 hours and down -3.85% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$367.60
Open:
$364.2
24h Volume:
2.41M
Relative Volume:
0.86
Market Cap:
$199.20B
Revenue:
$36.74B
Net Income/Loss:
$7.71B
P/E Ratio:
25.96
EPS:
14.2333
Net Cash Flow:
$8.10B
1W Performance:
-4.80%
1M Performance:
-3.85%
6M Performance:
+30.28%
1Y Performance:
+16.27%
1-Day Range:
$361.70
$369.76
1-Week Range:
$361.39
$391.29
52-Week Range:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
369.53 | 198.16B | 36.74B | 7.71B | 8.10B | 14.23 |
|
LLY
Lilly Eli Co
|
990.33 | 878.04B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
240.40 | 577.48B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
230.11 | 410.83B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
160.12 | 307.23B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
194.22 | 306.31B | 58.80B | 10.24B | 8.98B | 3.2788 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
American Century Companies Inc. Raises Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Xgeva Market Booming with Rapid Growth Through 2033 | Amgen • Novartis • Pfizer • Eli Lilly - openPR.com
Kyowa Kirin discontinues rocatinlimab trials due to safety issues - bioworld.com
Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities - Yahoo Finance
Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report? - Yahoo! Finance Canada
Amgen Inc. (NASDAQ:AMGN) Plans Quarterly Dividend of $2.52 - MarketBeat
Amgen: Wait For A Better Entry Point (Rating Downgrade) (NASDAQ:AMGN) - Seeking Alpha
ARK Investment Management LLC Sells 10,668 Shares of Amgen Inc. $AMGN - MarketBeat
Cytokines Market Global Forecast 2026-2032: Precise Treatments, Strategic Partnerships, and Supply Chain Resilience Fueling the $95+ Billion Market - GlobeNewswire Inc.
CI Investments Inc. Has $6.34 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Is Amgen (AMGN) Pricing Reflect Its Recent 24% One Year Share Price Return - Yahoo! Finance Canada
Amgen (AMGN) Maintains Quarterly Dividend of $2.52 Per Share - GuruFocus
Amgen Keeps Quarterly Dividend at $2.52 a Share, Payable June 5 to Holders of Record May 15 - marketscreener.com
AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND - Amgen
Amgen announces 2026 second quarter dividend - marketscreener.com
Amgen Advances Blinatumomab Franchise With New Phase 3 Subcutaneous Trial - TipRanks
Dimensional Fund Advisors Boosts Amgen Holdings - National Today
Smith Chas P & Associates PA Cpas Sells 47,455 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Victory Capital Management Inc. - MarketBeat
Mcdonald Partners LLC Decreases Holdings in Amgen Inc. $AMGN - MarketBeat
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.
Dimensional Fund Advisors LP Raises Holdings in Amgen Inc. $AMGN - MarketBeat
Is It Time To Reassess Amgen (AMGN) After Its Strong Multi Year Share Price Run? - simplywall.st
AMGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Amgen, Inc. Hits New 52-Week High of USD 390.14 - Markets Mojo
Amgen Inc. (AMGN) is Drawing Interest from Investors: Key Information You Need to Know - Bitget
Amgen EVP Sold $20.77M In Company Stock - Benzinga
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Amgen stock forecast for 2030: $6B patent exposure challenges $500 level - Traders Union
Fisher Asset Management LLC Acquires 375,463 Shares of Amgen Inc. $AMGN - MarketBeat
IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook - Stocktwits
Amgen (NASDAQ:AMGN) Sets New 1-Year HighShould You Buy? - MarketBeat
Amgen (NASDAQ:AMGN) Hits Annual High Within The Nasdaq 100 Index Rally - Kalkine Media
Amgen Touts Broad Portfolio Momentum, MariTide Milestones and Repatha Access Push at TD Cowen Conf - MarketBeat
Amgen Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S Revenue Breakdown – NEO:AMGN - TradingView
How North Carolina Attracted Amgen and Roche To Become a Next-Gen Obesity Drug Production Hotspot - BioSpace
Amgen (AMGN) EVP Esteban Santos exercises options and sells 54,792 shares - Stock Titan
Amgen at TD Cowen Conference: Strategic Growth and Challenges - Investing.com India
Amgen Is Up 35% in the Last 6 Months. Here’s Where the Stock Could Go in 2026 - TIKR.com
Amgen’s Phase 3 Gout Trial Pits Subcutaneous Pegloticase Against IV Dosing - TipRanks
Amgen Inc. (AMGN) Stock Report: Evaluating the 106% Return on Equity and Market Prospects - DirectorsTalk Interviews
Laurel Wealth Advisors LLC Cuts Position in Amgen Inc. $AMGN - MarketBeat
Bahl & Gaynor Inc. Lowers Stock Holdings in Amgen Inc. $AMGN - MarketBeat
6,843 Shares in Amgen Inc. $AMGN Purchased by 111 Capital - MarketBeat
Amgen Deployed a Record $7.2 Billion in R&D: Here’s What Investors Should Expect - TIKR.com
How Amgen’s $4 Billion Long-Dated Bond Issuance At Amgen (AMGN) Has Changed Its Investment Story - Yahoo Finance
Amgen Recasts Growth Story With Product Momentum And Long Dated Funding - simplywall.st
Amgen Inc. (AMGN): A Bull Case Theory - Insider Monkey
Andra AP fonden Boosts Stake in Amgen - National Today
Harvest Portfolios Group Inc. Boosts Holdings in Amgen Inc. $AMGN - MarketBeat
Argent Trust Co Lowers Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.83%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):